Valeant's turn in the hot seat

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) lost $32.97 (17%) to $166.50 in New York on Monday after congressional Democrats released a Turing Pharmaceuticals AG (New York, N.Y.) CEO Martin Shkreli. It links Valeant with Turing, asserting that Valeant "is using precisely the same business model."

Chaffetz had not replied to the requests for the subpoena and hearing as of Monday evening, a spokesperson for committee Democrats told BioCentury. ...